[New oral anticoagulants - influence on coagulation tests]

Area of Science:

• Pharmacology
• Clinical Chemistry
• Hematology

Background:

• New oral anticoagulants (NOACs) are increasingly used for thromboembolic disease prevention and treatment.
• NOACs target specific clotting factors, namely Factor Xa or Factor IIa (thrombin).
• These agents can interfere with standard coagulation laboratory assays.

Purpose of the Study:

• To elucidate the impact of specific NOACs on common coagulation assays.
• To highlight the variability in laboratory results influenced by NOACs.
• To guide the correct interpretation of coagulation tests in patients receiving NOAC therapy.

Main Methods:

• Review of the mechanisms of action for apixaban, rivaroxaban (Factor Xa inhibitors), and dabigatran (thrombin inhibitor).
• Analysis of the influence of these NOACs on prothrombin time (PT) and activated partial thromboplastin time (aPTT) assays.
• Examination of how drug half-life and reagent variations affect assay results.

Main Results:

• NOACs demonstrate varied effects on coagulation assays, dependent on their specific inhibitory action (Factor Xa vs. IIa).
• Assay results fluctuate significantly over 24 hours due to the short half-life of NOACs.
• Differences in laboratory findings are also attributed to the specific reagents employed in the assays.

Conclusions:

• The interpretation of coagulation assays in patients on NOACs requires awareness of drug-specific effects and assay methodologies.
• Understanding the interplay between NOACs, their mechanism of action, and coagulation assay principles is essential for clinical decision-making.
• Accurate monitoring and interpretation are vital for optimizing antithrombotic therapy with NOACs.